Objectives: To determine whether aztreonam is still an effective drug for the treatment of gonorrhoea.
Introduction
In recent decades, the number of infections due to Neisseria gonorrhoeae has risen inexorably, particularly in MSM and HIVinfected patients. In addition, due to the emergence and increase of infections caused by gonococci with reduced susceptibility to cephalosporins, treatment of gonorrhoea has become a public health issue. 1 In Europe, the proportion of strains resistant to cefixime (MIC .0.125 mg/L) increased 4-fold between 2011 (0.7%) and 2012 (3.0%). Unfortunately, this resistance to cefixime was associated with an increasing proportion of strains with reduced susceptibility to ceftriaxone (MICs 0.032 mg/L), which accounted for 6.4% of the resistant strains in the same period. 2 In such a context, azithromycin is being recommended by guidelines potentially to slow the emergence and spread of resistance to cephalosporins. Nevertheless, even if the prevalence of azithromycin-resistant N. gonorrhoeae isolates remains low and essentially due to multiple genetic mutations, 3 some concerns have been raised. Moreover, there is a lack of alternative therapy in patients allergic to penicillin. Serious allergy can occur in patients receiving penicillin therapy, with an estimated frequency of 1-5 per 10 000 cases. However, there is no allergic cross-reactivity between aztreonam and penicillin. 4 Although European guidelines recommend using spectinomycin if resistance to extended-spectrum cephalosporins is identified or suspected, or if a patient has history of penicillin anaphylaxis, this agent has been unavailable for some time in most European countries, including France and the USA. 5 Therefore, patients allergic to penicillin mostly receive ceftriaxone or high-dose oral azithromycin (2 g); however, the widespread use of these drugs poses selective pressure for the emergence of resistance. 6 Treating gonorrhoea is thus a challenge, particularly as resistance to the previously recommended agent, ciprofloxacin, is widespread. 7 Moreover, diagnosis of gonorrhoea may be based on PCR, and so physicians lack results of antimicrobial susceptibility testing normally undertaken when organisms are cultured.
In light of the above, we decided to conduct an ongoing observational study of the use of aztreonam as a first-line regimen in patients known to be allergic to b-lactams, or in second-line treatment in case of a prior treatment failure.
Patients and methods
We included patients with gonorrhoea diagnosed by urine multiplex PCR, with a past medical history of allergy to b-lactams (including penicillin) or relapse after a third-generation cephalosporin regimen. Patients were recruited on the basis that they were either known to be allergic to b-lactams, or had been previously treated with a cephalosporin and relapsed within a month.
All patients were adults and were warned of the potential risk of crossreaction between monobactams and b-lactams, even though the risk is believed to be low. They all gave oral consent to be treated.
Ethics
As part of routine care, all procedures performed involving human participants were in accordance with the ethics standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethics standards. For this type of study, formal consent is not required.
Results
Five patients were included. Median age was 38 years old (range 23-51). Patient characteristics are detailed in Table 1 . Two were known to be allergic to b-lactams (one to penicillin, the other to a cephalosporin), while the remainder were previously treated for gonorrhoea with cephalosporins and relapsed.
Aztreonam was administered either by the intravenous or intramuscular routes. All five patients were assessed as cured without any adverse event. Because the patients were tested by direct urine multiplex PCR, we could not assess the aztreonam MICs of the causative strains. Nevertheless, we are confident that aztreonam was effective as all four males were free of symptoms, and the woman was tested negative for gonorrhoea after 1 month.
Discussion
In the literature, most of the studies of aztreonam treatment of gonorrhoea were published before the appearance of resistance to recent antibiotics, particularly fluoroquinolones and cephalosporins. The first report of single-dose aztreonam treatment in acute uncomplicated gonococcal urethritis in men was published in 1983 and reported 100% efficacy (n " 51). 8 Later on, concerns about penicillin-resistant gonorrhoea led to interest in aztreonam, which received FDA approval on 31 December 1986. In 1992, one in vitro study revealed that among 333 gonococcal isolates, none was resistant to aztreonam (MIC ,8 mg/L). 9 However, aztreonam use declined when oral fluoroquinolones appeared for the treatment of gonorrhoea.
The latest review of the literature issued by the US CDC in 1995, 10 which served as a baseline for the latest guidelines, did not retain aztreonam as a highly effective drug against gonorrhoea because of lack of efficacy against pharyngeal infection (66.6%), although this finding was based on a very small sample size (n " 3). 11 Since that publication, no new data have become available to assess adequately the efficacy of aztreonam, particularly because fluoroquinolones and cephalosporins were widely used in the treatment of gonorrhoea in the last two decades. Nevertheless, this result regarding pharyngeal decolonization is not sufficient to decide whether an antimicrobial treatment is effective to reduce the spread of gonorrhoea. Indeed, spectinomycin does not provide better results in terms of pharyngeal decolonization (51.8%) in spite of a higher sample size (n " 56) than the study of treatment with aztreonam. 10 It is interesting to note that only a few publications have raised concerns about aztreonam-resistant N. gonorrhoeae, particularly in Japan. One is an in vitro study 12 where strains had also a reduced susceptibility to ceftriaxone (MICs " 0.125 mg/L), whereas another study reported one case of a patient infected with a gonococcal strain resistant to aztreonam as well as cefozopran. 13 Recently, some strains of N. gonorrhoeae with reduced susceptibility to ceftriaxone [H041 (MIC " 2 mg/L), F89 (MIC " 1 mg/L) and A8806/G140106 (MIC " 0.5 mg/L)] have been described, but none was tested against aztreonam. 14, 15 It is notable that aztreonam has the same route of administration as ceftriaxone, but has the advantage of a lack of disturbance of the gut flora due to lower biliary excretion (,1%) than ceftriaxone (45%), as mentioned in the summary of product characteristics. Moreover, some concerns can be raised by recent literature reports of increasing treatment failure of single-dose cephalosporins in the treatment of pharyngeal infections due to N. gonorrhoeae (Table 2) . Indeed, international guidelines based their recommendation of third-generation cephalosporins as a first-line regimen partly because they had historically a higher rate of pharyngeal eradication (98.9%), 10 which should now be balanced with the lack of recent microbiological data concerning other drugs such as aztreonam.
Altogether, this report argues for a rethinking of the management of gonococcal urethritis, particularly when patients are infected by strains with reduced susceptibility to ceftriaxone or are known to be allergic to penicillin.
The preliminary results of this ongoing study are encouraging. Further clinical trials are needed to demonstrate that the riskbenefit balance remains favourable and that no resistance has emerged. Aztreonam as a new treatment strategy for gonorrhoea JAC
